Zydus receives USFDA tentative approval Valbenazine Capsules

17 Oct 2022 , 11:29 AM

Zydus Lifesciences subsidiary Zydus Worldwide DMCC has received tentative approval from the United States Food and Drug Administration (USFDA) to market Valbenazine Capsules USP 40 mg, 60 mg, and 80 mg (USRLD: Ingrezza?). Valbenazine Capsules are indicated for the treatment of adults with tardive dyskinesia (movements in the face, tongue, or other body parts that cannot be controlled). The drug will be manufactured at the groups formulation manufacturing facility at Ahmedabad SEZ, India. Powered by Capital Market – Live News